Article info
Review
The role of biosimilars in the treatment of rheumatic diseases
- Correspondence to Professor Thomas Dörner, CC12 Department of Medicine, Rheumatology and Clinical Immunology, Charité—University Medicine Berlin, Chariteplatz 1, Berlin 10117, Germany;thomas.doerner{at}charite.de
Citation
The role of biosimilars in the treatment of rheumatic diseases
Publication history
- Received September 21, 2012
- Revised November 23, 2012
- Accepted December 2, 2012
- First published December 19, 2012.
Online issue publication
February 05, 2013
Article Versions
- Previous version (19 December 2012).
- Previous version (21 December 2012).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions